Palbociclib
Top HER2-positive breast cancer news from SABCS
San Antonio Breast Cancer Symposium 2024 provided multiple updates in the field of HER2-positive breast cancer, including novel treatments, new treatment regimens and more.
Targeted therapies for breast cancer increase thrombosis risk
SAN DIEGO — The true incidence of thrombosis among people who received targeted therapy for breast cancer is significantly higher than reported in prior clinical trials, according to study results.
Medicare selects 15 drugs for second round of price negotiations, including semaglutide
CMS has selected 15 new drugs for the next round of Medicare Part D price negotiations, according to a press release from HHS.
Palbociclib regimen extends PFS in double-positive metastatic breast cancer
SAN ANTONIO — The addition of palbociclib to standard care extended median PFS for patients with hormone receptor-positive, HER2-positive metastatic breast cancer, according to study results presented at San Antonio Breast Cancer Symposium.
Inavolisib regimen extends PFS in PIK3CA-mutated advanced breast cancer
The addition of inavolisib to palbociclib and fulvestrant more than doubled PFS for certain patients with advanced breast cancer, according to results of a randomized phase 3 trial.
FDA approves Itovebi regimen for advanced breast cancer
The FDA approved inavolisib as part of combination therapy for certain adults with breast cancer.
Oncologist receives Szent-Györgyi Prize for groundbreaking research discoveries
Dennis J. Slamon, MD, PhD, received the Szent-Györgyi Prize for Progress in Cancer Research.
Chemotherapy-free regimen induces ‘high’ clinical benefit rate in metastatic breast cancer
SAN ANTONIO — A four-therapy combination conferred clinical benefit to nearly all evaluable patients with metastatic triple-positive breast cancer, according to findings of the ASPIRE trial presented at San Antonio Breast Cancer Symposium.
Combination yields ‘promising PFS outcomes’ in certain patients with breast cancer
SAN ANTONIO — The combination of zanidatamab, palbociclib and fulvestrant yielded promising PFS results among adults with HER2-positive/hormone receptor-positive metastatic breast cancer, findings from a phase 2A study showed.
Early progression on CDK4/6 regimen a ‘strong’ predictor of OS in breast cancer subset
SAN ANTONIO — The addition of either fulvestrant or letrozole to palbociclib conferred similar efficacy among patients with HER2-negative advanced breast cancer, according to data presented at San Antonio Breast Cancer Symposium.